Signals
Merck KGaA’s Saturnus Bio bet signals a shift to genotype-driven cardiology, and a looming readiness gap for health systems
Merck KGaA’s $50 million build-to-buy collaboration with Versant Ventures to launch Saturnus Bio signals growing industry interest in rare genetic cardiomyopathies. The science is moving toward targeted gene modulation and genotype-defined treatment. The policy challenge is whether health systems can build the genetic testing, counselling, family screening and reimbursement pathways needed to make precision cardiology…
Europe’s Epilepsy Rules Start Catching Up With Precision Treatment
SMA Screening Shows Precision Neurology Starts Before Symptoms
Post-Stroke Cognitive Screening Needs Local Tools
Europe’s Stroke Plan Turns Speed Into a Policy Test
Parkinson’s Research Moves From Tracking Progression to Defining Biology
MS Monitoring Starts Moving Beyond the MRI Bottleneck
Latin America Challenges the Dementia Biomarker Evidence Gap
China’s Alzheimer’s Blood-Test Rollout Turns Diagnosis Into an Access Market
Alzheimer’s Blood Testing Moves Toward Routine Care
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.